查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529611

T 細胞淋巴瘤 (TCL) 市場規模、佔有率和趨勢分析：按類型、療法、地區和細分市場預測，2024-2030 年

T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type (Peripheral, Lymphoblastic), By Therapy (Radiotherapy, Immunotherapy, Stem Cell Transplantation), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

T 細胞淋巴瘤 (TCL) 市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球T細胞淋巴瘤（TCL）市場規模將達37億美元，2024年至2030年複合年成長率為8.83%。

由於製藥公司治療方案和策略性舉措的進步，TCL 市場正在顯著擴張。 14種新藥的推出和新適應症治療方法的擴展是推動這一成長的關鍵因素。這些進展旨在為患者提供傳統化療以外更多的治療選擇，而傳統化療一直是TCL治療的基石。

2023 年，美國報告了大約 12,600 例外週 T 細胞淋巴瘤 (PTCL) 新病例，預計到 2030 年這一數字將增加，反映出疾病盛行率的增加。此外，2023年美國、法國、德國、義大利、西班牙、英國和日本等市場的非何傑金氏淋巴瘤（NHL）CAR-T療法總合約155,300例。 CAR-T 療法的產品線多種多樣，針對不同的發展階段，主要集中在 B 細胞淋巴瘤，但人們對 PTCL 治療也重新產生了興趣。

目前，以細胞週期蛋白藥物為基礎的化療方案（如 CHOP 和 CHOEP）是新診斷 PTCL 患者的標準第一線治療方法。然而，CHP-BV 等治療 ALCL 的新方法代表了向更有針對性的治療的轉變，從而提高了治療效果。此外，日本在針對 ATLL 和 R/R PTCL 推出 HIYASTA、DARVIAS 和 REMITORO 等藥物方面取得了重大進展，擴大了治療選擇並推動了市場成長。這些創新為獲得更好的結果帶來了希望，特別是對於治療方法選擇有限的患者。

CAR-T細胞治療和NK細胞治療領域也不斷進步，從臨床前階段轉向大規模臨床研究。這些創新方法為個人化 TCL 治療提供了廣闊的前景。此外，針對特定 TCL 相關蛋白和訊號的生物製藥正在開發中，包括 PD-1/PD-L1 抑制劑、NK 細胞接合劑、抗 CD47 抗體以及針對 CCR4 的 mogamulizumab 等藥物。這些進步旨在創建更精確的治療平台並有可能改善患者的治療結果。

未來，製藥公司的策略性舉措預計將在 2030 年之前顯著改變市場，尤其是在日本和美國。這些舉措包括將現有藥物帶入新市場、探索新的治療方法以及專注於針對 TCL 亞型量身定做的尚未充分研究的標靶。

然而，市場面臨標準治療專利到期等挑戰，並面臨可能影響銷售的學名藥競爭。然而，新藥進入市場預計將緩解這些挑戰並保持成長勢頭。

武田製藥 (Takeda Pharmaceuticals)、百時美施貴寶 (Bristol-Myers Squibb) 和諾華 (Novartis) 等主要企業，以及 Citius Pharmaceuticals、Innate Pharma 和 Soligenix 等新興企業，在推動市場動態方面發揮關鍵作用。 ADCETRIS 和 POTELIGEO 等創新療法對於滿足 TCL 治療需求至關重要。諾華對CAR-T療法的承諾凸顯了持續創新，而I/ONTAK（E7777）、SGX301和Lacutamab等新療法也將進一步豐富TCL的管理策略。這些公司對於透過策略性舉措和開創性治療來塑造 TCL 的未來格局至關重要。

T 細胞淋巴瘤 (TCL) 市場報告亮點

  • 按類型分類，外周T細胞淋巴瘤（PTCL）細分市場佔據最大的銷售佔有率，2023年為66.47%。
  • 以療法來看，化療佔最大銷售佔有率，2023年為26.69%。多年來，化療一直是TCL治療的基石，常用的方案包括CHOP（Cyclophosphamide、阿黴素、長春新鹼、潑尼松）和CHOEP（Cyclophosphamide、阿黴素、長春新鹼、Etoposide、潑尼松）。這些治療方法因其在疾病管理方面的有效性而廣受認可，通常是新診斷患者的首選治療方法。
  • 預計免疫治療領域在預測期內成長最快，達 7.21%。這種快速成長是由重大進步和新治療方法利用人體的免疫系統更精確地瞄準癌細胞。
  • 在先進的醫療基礎設施、高昂的醫療成本以及正在進行的大量研發的推動下，北美將成為最大的市場，到 2023 年，其佔有率將達到 37.67%。

目錄

第1章調查方法和範圍

第2章 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
  • 市場動態
    • 免疫治療和標靶治療的進展
    • 全球 T 細胞淋巴瘤 (TCL) 的發生率正在增加
    • 新治療方法的監管核准和適應症的擴大
  • 市場限制因素分析
    • 創新治療方法高成本
    • 發展中地區識別和診斷的局限性
  • 營商環境分析
    • SWOT 分析；按因素（政治/法律、經濟/技術）
    • 波特五力分析
  • COVID-19 影響分析

第3章 T 細胞淋巴瘤（TCL）市場：類型業務分析

  • 類型市場佔有率，2023年及2030年
  • 細分儀表板
  • T 細胞淋巴瘤 (TCL) 市場：按類型分類的展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 周邊
  • 淋巴母細胞的

第4章 T 細胞淋巴瘤（TCL）市場：治療業務分析

  • 2023年及2030年治療市場佔有率
  • 細分儀表板
  • T 細胞淋巴瘤 (TCL) 市場：依治療方法展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 放射線治療
  • 化療
  • 免疫療法
  • 幹細胞移植
  • 其他

第5章 T 細胞淋巴瘤（TCL）市場：區域業務分析

  • 2023年及2030年T細胞淋巴瘤（TCL）按地區市場佔有率
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第6章 競爭狀況

  • 參與企業概況
  • 財務表現
  • 參與企業
    • 市場領導者
    • 2023 年 T 細胞淋巴瘤 (TCL)市場佔有率分析
    • 公司簡介
    • 策略規劃
Product Code: GVR-4-68040-318-4

T-cell Lymphoma Market Growth & Trends:

The global T-cell lymphoma market size is anticipated to reach USD 3.70 billion by 2030, expanding at a CAGR of 8.83% from 2024 to 2030, according to a new report by Grand View Research, Inc. The TCL market is expanding substantially, driven by advancements in treatment options and strategic initiatives by pharmaceutical companies. The introduction of 14 new pipeline agents and expanded therapies for new indications are key factors fueling this growth. These developments aim to provide patients with more treatment choices beyond traditional chemotherapy, which has been a cornerstone in TCL therapy.

In 2023, the U.S. reported around 12,600 new cases of Peripheral T-Cell Lymphoma (PTCL), a number expected to rise by 2030, reflecting an increasing disease incidence. Moreover, CAR-T therapies for Non-Hodgkin Lymphoma (NHL) in markets such as the United States, France, Germany, Italy, Spain, UK, and Japan totaled approximately 155,300 cases in 2023. The pipeline for CAR-T therapies is diverse, targeting various stages of development and focusing mainly on B-cell Lymphoma types, with emerging interest in PTCL treatments.

Currently, anthracycline-based chemotherapy remains standard for newly diagnosed PTCL patients, with regimens like CHOP or CHOEP being typical first-line treatments. However, newer approaches such as CHP-BV for ALCL illustrate a shift towards more targeted therapies, enhancing treatment efficacy. Additionally, Japan has seen significant advancements with the introduction of drugs like HIYASTA, DARVIAS, and REMITORO for ATLL and R/R PTCL, expanding treatment options and driving market growth. These innovations provide hope for better outcomes, particularly for patients with limited therapeutic choices.

The field of CAR-T and NK cell therapies is also progressing, moving from preclinical phases to larger clinical studies. These innovative approaches offer promising prospects for personalized TCL treatments. In addition, biologics targeting specific TCL-related proteins and signals are under development, including PD-1/PD-L1 inhibitors, NK-cell engagers, anti-CD47 antibodies, and drugs like mogamulizumab targeting CCR4. These advancements aim to create more precise treatment platforms, potentially improving patient outcomes.

Looking ahead, strategic initiatives by pharmaceutical companies are expected to drive significant market changes by 2030, particularly in Japan and the U.S. These initiatives include introducing established drugs into new markets, exploring novel treatment approaches, and focusing on under-researched targets tailored to TCL subtypes.

However, the market faces challenges such as patent expires on standard treatments, leading to generic competition that could impact sales. Nonetheless, the entry of new agents into the market is anticipated to mitigate these challenges and sustain growth momentum.

Key players like Takeda Pharmaceuticals, Bristol-Myers Squibb, and Novartis are pivotal in driving market dynamics, alongside emerging firms such as Citius Pharmaceuticals, Innate Pharma, and Soligenix. Their innovative therapies like ADCETRIS and POTELIGEO are crucial in meeting TCL treatment needs. Novartis's commitment to CAR-T therapies underscores ongoing innovation, while emerging treatments like I/ONTAK (E7777), SGX301, and Lacutamab are poised to further enrich TCL management strategies. These companies are pivotal in shaping the future TCL landscape through strategic initiatives and pioneering treatments.

T-cell Lymphoma Market Report Highlights:

  • Based on type, the Peripheral T-Cell Lymphoma (PTCL) segment held the largest revenue share of 66.47% in 2023
  • Based on therapy, the chemotherapy segment held the largest revenue share of 26.69% in 2023. For many years, chemotherapy has been the cornerstone of TCL treatment, with regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) being commonly used. These regimens are widely recognized for their effectiveness in managing disease and are typically the first line of treatment for newly diagnosed patients
  • The Immunotherapy segment is expected to grow with a fastest growth rate of 7.21% over the forecast period. This rapid growth is driven by significant advancements and the introduction of novel therapies that harness the body's immune system to target cancer cells more precisely
  • North America represents the largest market with share of 37.67% in 2023, driven by advanced healthcare infrastructure, high healthcare expenditure, and significant ongoing research and development

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Therapy
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Market Variables, Trends, & Scope

  • 2.1. Market Segmentation and Scope
  • 2.2. Market Lineage Outlook
    • 2.2.1. Parent Market Outlook
    • 2.2.2. Related/Ancillary Market Outlook
  • 2.3. Market Trends and Outlook
  • 2.4. Market Dynamics
    • 2.4.1. Advances in Immunotherapy and Targeted Therapies
    • 2.4.2. Increasing Prevalence of T-cell Lymphoma Globally
    • 2.4.3. Regulatory Approvals and Expanded Indications for Novel Treatments
  • 2.5. Market Restraint Analysis
    • 2.5.1. High Cost of Innovative Therapies
    • 2.5.2. Limited Awareness and Diagnosis in Developing Regions
  • 2.6. Business Environment Analysis
    • 2.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 2.6.2. Porter's Five Forces Analysis
  • 2.7. COVID-19 Impact Analysis

Chapter 3. T-cell Lymphoma Market: Type Business Analysis

  • 3.1. Type Market Share, 2023 & 2030
  • 3.2. Segment Dashboard
  • 3.3. T-cell Lymphomas Market by Type Outlook
  • 3.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 3.5. Peripheral
    • 3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 3.5.2. Cutaneous T-cell Lymphoma
      • 3.5.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 3.5.3. Anaplastic Large Cell Lymphoma
      • 3.5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 3.5.4. Angio-immuno-blastic T-cell Lymphoma
      • 3.5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 3.5.5. Other
      • 3.5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 3.6. Lymphoblastic
    • 3.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 4. T-cell Lymphoma Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. T-cell Lymphomas Market by Therapy Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Radiotherapy
    • 4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Immunotherapy
    • 4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Stem Cell Transplantation
    • 4.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Other
    • 4.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. T-cell Lymphoma Market: Regional Business Analysis

  • 5.1. T-cell Lymphoma Market Share By Region, 2023 & 2030
  • 5.2. North America
    • 5.2.1. U.S.
      • 5.2.1.1. Key Country Dynamics
      • 5.2.1.2. Target Disease Prevalence
      • 5.2.1.3. Competitive Scenario
      • 5.2.1.4. Regulatory Framework
      • 5.2.1.5. Reimbursement Scenario
      • 5.2.1.6. U.S. T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.2.2. Canada
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Target Disease Prevalence
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. Regulatory Framework
      • 5.2.2.5. Reimbursement Scenario
      • 5.2.2.6. Canada T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.2.3. Mexico
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. Reimbursement Scenario
      • 5.2.3.6. Mexico T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe T-cell Lymphomas Market, 2018 - 2030 (USD Million)
    • 5.3.2. Germany
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Target Disease Prevalence
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Regulatory Framework
      • 5.3.2.5. Reimbursement Scenario
      • 5.3.2.6. Germany T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. Reimbursement Scenario
      • 5.3.3.6. UK T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Target Disease Prevalence
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. Regulatory Framework
      • 5.3.4.5. Reimbursement Scenario
      • 5.3.4.6. France T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Target Disease Prevalence
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Regulatory Framework
      • 5.3.5.5. Reimbursement Scenario
      • 5.3.5.6. Italy T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Target Disease Prevalence
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Regulatory Framework
      • 5.3.6.5. Reimbursement Scenario
      • 5.3.6.6. Spain T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.7. Denmark
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Target Disease Prevalence
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Regulatory Framework
      • 5.3.7.5. Reimbursement Scenario
      • 5.3.7.6. Denmark T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Target Disease Prevalence
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Regulatory Framework
      • 5.3.8.5. Reimbursement Scenario
      • 5.3.8.6. Sweden T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Target Disease Prevalence
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Regulatory Framework
      • 5.3.9.5. Reimbursement Scenario
      • 5.3.9.6. Norway T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Target Disease Prevalence
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Regulatory Framework
      • 5.4.2.5. Reimbursement Scenario
      • 5.4.2.6. Japan T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. Reimbursement Scenario
      • 5.4.3.6. China T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. Regulatory Framework
      • 5.4.4.5. Reimbursement Scenario
      • 5.4.4.6. India T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Target Disease Prevalence
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Regulatory Framework
      • 5.4.5.5. Reimbursement Scenario
      • 5.4.5.6. South Korea T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Target Disease Prevalence
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Regulatory Framework
      • 5.4.6.5. Reimbursement Scenario
      • 5.4.6.6. Australia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Target Disease Prevalence
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. Regulatory Framework
      • 5.4.7.5. Reimbursement Scenario
      • 5.4.7.6. Thailand T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Target Disease Prevalence
      • 5.5.2.3. Competitive Scenario
      • 5.5.2.4. Regulatory Framework
      • 5.5.2.5. Reimbursement Scenario
      • 5.5.2.6. Brazil T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.5.3. Argentina
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Regulatory Framework
      • 5.5.3.5. Reimbursement Scenario
      • 5.5.3.6. Argentina T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. MEA T-cell Lymphoma Market,, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Target Disease Prevalence
      • 5.6.2.3. Competitive Scenario
      • 5.6.2.4. Regulatory Framework
      • 5.6.2.5. Reimbursement Scenario
      • 5.6.2.6. South Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Regulatory Framework
      • 5.6.3.5. Reimbursement Scenario
      • 5.6.3.6. Saudi Arabia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. Regulatory Framework
      • 5.6.4.5. Reimbursement Scenario
      • 5.6.4.6. UAE T-cell Lymphoma Market, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Regulatory Framework
      • 5.6.5.5. Reimbursement Scenario
      • 5.6.5.6. Kuwait T-cell Lymphoma Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant's overview
  • 6.2. Financial performance
  • 6.3. Participant categorization
    • 6.3.1. Market Leaders
    • 6.3.2. T-cell Lymphoma Market Share Analysis, 2023
    • 6.3.3. Company Profiles
      • 6.3.3.1. Acrotech Biopharma
      • 6.3.3.1.1. Company Overview
      • 6.3.3.1.2. Financial Performance
      • 6.3.3.1.3. Product Benchmarking
      • 6.3.3.1.4. Strategic Initiatives
      • 6.3.3.2. Affimed GmbH
      • 6.3.3.2.1. Company Overview
      • 6.3.3.2.2. Financial Performance
      • 6.3.3.2.3. Product Benchmarking
      • 6.3.3.2.4. Strategic Initiatives
      • 6.3.3.3. Bristol Myers Squibb
      • 6.3.3.3.1. Company Overview
      • 6.3.3.3.2. Financial Performance
      • 6.3.3.3.3. Product Benchmarking
      • 6.3.3.3.4. Strategic Initiatives
      • 6.3.3.4. Chipscreen Biosciences
      • 6.3.3.4.1. Company Overview
      • 6.3.3.4.2. Financial Performance
      • 6.3.3.4.3. Product Benchmarking
      • 6.3.3.4.4. Strategic Initiatives
      • 6.3.3.5. Citius Pharma
      • 6.3.3.5.1. Company Overview
      • 6.3.3.5.2. Financial Performance
      • 6.3.3.5.3. Product Benchmarking
      • 6.3.3.5.4. Strategic Initiatives
      • 6.3.3.6. DAIICHI SANKYO COMPANY, LIMITED
      • 6.3.3.6.1. Company Overview
      • 6.3.3.6.2. Financial Performance
      • 6.3.3.6.3. Product Benchmarking
      • 6.3.3.6.4. Strategic Initiatives
      • 6.3.3.7. Eisai Co., Ltd.
      • 6.3.3.7.1. Company Overview
      • 6.3.3.7.2. Financial Performance
      • 6.3.3.7.3. Product Benchmarking
      • 6.3.3.7.4. Strategic Initiatives
      • 6.3.3.8. Genor Biopharma Co. Ltd
      • 6.3.3.8.1. Company Overview
      • 6.3.3.8.2. Financial Performance
      • 6.3.3.8.3. Product Benchmarking
      • 6.3.3.8.4. Strategic Initiatives
      • 6.3.3.9. Innate Pharma
      • 6.3.3.9.1. Company Overview
      • 6.3.3.9.2. Financial Performance
      • 6.3.3.9.3. Product Benchmarking
      • 6.3.3.9.4. Strategic Initiatives
      • 6.3.3.10. Dizal Pharma
      • 6.3.3.10.1. Company Overview
      • 6.3.3.10.2. Financial Performance
      • 6.3.3.10.3. Product Benchmarking
      • 6.3.3.10.4. Strategic Initiatives
    • 6.3.4. Strategy Mapping
      • 6.3.4.1. Expansion
      • 6.3.4.2. Acquisition
      • 6.3.4.3. Collaborations
      • 6.3.4.4. Product/Service Launch
      • 6.3.4.5. Partnerships
      • 6.3.4.6. Others

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global T-cell Lymphoma Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 5 Global T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 6 North America T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 8 North America T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 9 U.S. T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 12 Canada T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 13 Mexico T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 15 Europe T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 17 Europe T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 18 Germany T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 19 Germany T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 20 UK T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 21 UK T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 22 France T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 23 France T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 24 Italy T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 25 Italy T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 26 Denmark T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 27 Denmark T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 28 Sweden T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 29 Sweden T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 30 Norway T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 31 Norway T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 35 China T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 36 China T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 37 Japan T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 38 Japan T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 39 India T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 40 India T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 41 South Korea T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 42 South Korea T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 43 Australia T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 44 Australia T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 45 Thailand T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 46 Thailand T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 47 Latin America T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Latin America T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 49 Latin America T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 50 Brazil T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 51 Brazil T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 52 Argentina T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 53 Argentina T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 54 Middle East & Africa T-cell Lymphoma Market, by Country, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 57 South Africa T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 58 South Africa T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 61 UAE T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 62 UAE T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 63 Kuwait T-cell Lymphoma Market, Type, 2018 - 2030 (USD Million)
  • Table 64 Kuwait T-cell Lymphoma Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 65 Financial performance
  • Table 66 Key companies undergoing expansions
  • Table 67 Key companies undergoing acquisitions
  • Table 68 Key companies undergoing collaborations
  • Table 69 Key companies launching new products/services
  • Table 70 Key companies undergoing partnerships
  • Table 71 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 T-cell Lymphoma Market Segmentation
  • Fig. 7 Market Snapshot, 2023
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global T-cell Lymphoma Market: By Type, Movement Analysis
  • Fig. 15 Global T-cell Lymphoma Market, for Peripheral, 2018 - 2030 (USD Million)
  • Fig. 16 Global T-cell Lymphoma Market, for Cutaneous T-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 17 Global T-cell Lymphoma Market, for Anaplastic Large Cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 18 Global T-cell Lymphoma Market, for Angio-immuno-blastic T-cell Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 19 Global T-cell Lymphoma Market, for Other, 2018 - 2030 (USD Million)
  • Fig. 20 Global T-cell Lymphoma Market, for Lymphoblastic, 2018 - 2030 (USD Million)
  • Fig. 21 Global T-cell Lymphoma Market: By Therapy, Movement Analysis
  • Fig. 22 Global T-cell Lymphoma Market, for Radiotherapy, 2018 - 2030 (USD Million)
  • Fig. 23 Global T-cell Lymphoma Market, for Chemotherapy, 2018 - 2030 (USD Million)
  • Fig. 24 Global T-cell Lymphoma Market, for Immunotherapy, 2018 - 2030 (USD Million)
  • Fig. 25 Global T-cell Lymphoma Market, for Stem Cell Transplantation, 2018 - 2030 (USD Million)
  • Fig. 26 Global T-cell Lymphoma Market, for Other, 2018 - 2030 (USD Million)
  • Fig. 27 Regional Marketplace: Key Takeaways T-cell Lymphoma Market,
  • Fig. 28 Regional Outlook, 2023 & 2030 T-cell Lymphoma Market,
  • Fig. 29 Global T-cell Lymphoma Market: Region Movement Analysis
  • Fig. 30 North America T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 35 Germany T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 36 UK T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 37 France T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 38 Italy T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 45 China T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 46 India T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 47 Australia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 54 South Africa T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 56 UAE T-cell Lymphoma Market, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait T-cell Lymphoma Market, 2018 - 2030 (USD Million)